{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:11:58Z","timestamp":1765995118462,"version":"3.48.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,17]]},"DOI":"10.7759\/cureus.99473","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:09:40Z","timestamp":1765994980000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapidly Progressive Cerebellar Syndrome Associated With Anti-Yo Antibodies Following Complete Response to Advanced Ovarian Carcinoma Treated With Olaparib: A Case Report"],"prefix":"10.7759","author":[{"given":"Sara","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Rita","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus F","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, et al.. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021, 8:1014. 10.1212\/NXI.0000000000001014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.5.713","article-title":"Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies","volume":"55","author":"Rojas I","year":"2000","unstructured":"Rojas I, Graus F, Keime-Guibert F, et al.. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000, 55:713-15. 10.1212\/wnl.55.5.713","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon RM","year":"2019","unstructured":"Chabanon RM, Muirhead G, Krastev DB, et al.. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest. 2019, 129:1211-28. 10.1172\/JCI123319","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg133","article-title":"Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients","volume":"126","author":"Shams'ili S","year":"2003","unstructured":"Shams'ili S, Grefkens J, de Leeuw B, et al.. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003, 126:1409-18. 10.1093\/brain\/awg133","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1999.tb00226.x","article-title":"Paraneoplastic neurologic syndromes: pathogenesis and physiopathology","volume":"9","author":"Dalmau J","year":"1999","unstructured":"Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol. 1999, 9:275-84. 10.1111\/j.1750-3639.1999.tb00226.x","journal-title":"Brain Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-118","article-title":"Neurologic complications of cancer, 2nd ed","volume":"11","author":"Rogers LR","year":"2009","unstructured":"Rogers LR. Neurologic complications of cancer, 2nd ed. Neuro Oncol. 2009, 11:96-7. 10.1215\/15228517-2008-118","journal-title":"Neuro Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"2","author":"Gagnier JJ","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013, 2:38-43. 10.7453\/gahmj.2013.008","journal-title":"Glob Adv Health Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13584","article-title":"Olaparib dose re-escalation in ovarian cancer patients who experienced severe and\/or uncommon adverse events: a case series","volume":"17 Suppl 3","author":"Ngu SF","year":"2021","unstructured":"Ngu SF, Tse KY, Chu MM, Ngan HY, Chan KK. Olaparib dose re-escalation in ovarian cancer patients who experienced severe and\/or uncommon adverse events: a case series. Asia Pac J Clin Oncol. 2021, 17 Suppl 3:3-11. 10.1111\/ajco.13584","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-024-03771-w","article-title":"Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis","volume":"81","author":"Jin W","year":"2025","unstructured":"Jin W, Yang Q, Zhang Z, Li J. Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2025, 81:65-81. 10.1007\/s00228-024-03771-w","journal-title":"Eur J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen J","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, et al.. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019, 79:311-19. 10.1158\/0008-5472.CAN-18-1003","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-251277","article-title":"Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapy","volume":"16","author":"Giucca A","year":"2023","unstructured":"Giucca A, Morrison H, Wilson T, Cossburn M. Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapy. BMJ Case Rep. 2023, 16:251277. 10.1136\/bcr-2022-251277","journal-title":"BMJ Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.93267","article-title":"Paraneoplastic neurologic syndrome: a practical approach","volume":"15","author":"Kannoth S","year":"2012","unstructured":"Kannoth S. Paraneoplastic neurologic syndrome: a practical approach. Ann Indian Acad Neurol. 2012, 15:6-12. 10.4103\/0972-2327.93267","journal-title":"Ann Indian Acad Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007362","article-title":"Anti-Yo positive and late-onset paraneoplastic cerebellar degeneration associated with ovarian carcinoma: a case report","volume":"96","author":"Cui D","year":"2017","unstructured":"Cui D, Xu L, Li WY, Qian WD. Anti-Yo positive and late-onset paraneoplastic cerebellar degeneration associated with ovarian carcinoma: a case report. Medicine (Baltimore). 2017, 96:e7362. 10.1097\/MD.0000000000007362","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441632-rapidly-progressive-cerebellar-syndrome-associated-with-anti-yo-antibodies-following-complete-response-to-advanced-ovarian-carcinoma-treated-with-olaparib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:09:44Z","timestamp":1765994984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441632-rapidly-progressive-cerebellar-syndrome-associated-with-anti-yo-antibodies-following-complete-response-to-advanced-ovarian-carcinoma-treated-with-olaparib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.99473","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}